| APDN:Applied DNA Sciences Inc * | | Charting | News | Options |
*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements |
||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
10.17% $0.49
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Applied DNA Announces 1-For-20 Reverse Stock Split |
|
| ACCESSWIRE |
|
STONY BROOK, NY / ACCESSWIRE / April 22, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the Company), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-20 stock split of its common stock, to be effective as of 12:01 a.m. Eastern Time on Thursday, April 25, 2024. Applied DNA common stock will begin trading on a split-adjusted basis commencing upon market open on Thursday, April 25, 2024. |
| Full Story → |
|
| Headline News |
|
| Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start |
| 9:02a ET March 18 '24 ACCESSWIRE |
|
|
| Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress |
| 10:01a ET March 14 '24 ACCESSWIRE |
|
|
| Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results |
| 4:08p ET February 8 '24 ACCESSWIRE |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| Today, 10:14a ET Thursday April 25 '24. Markets Open. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 24 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
